Novel p53 therapies for head and neck cancer
Inactivation of the tumor suppressor p53 is the predominant pathogenetic event in head and neck squamous cell carcinoma (HNSCC). The p53 pathway in HNSCC can be compromised through multiple mechanisms including gene mutations, hyperactivation of endogenous negative p53 regulators and by the human pa...
Enregistré dans:
Auteurs principaux: | Mario R. Castellanos, Quintin Pan |
---|---|
Format: | article |
Langue: | EN |
Publié: |
KeAi Communications Co., Ltd.
2016
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/7f96e30f0f9547dda9dba2c79df9c3a2 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Novel therapeutics and emerging technologies in head and neck cancer
par: Theodoros N. Teknos, M.D.
Publié: (2016) -
The current status of oncolytic viral therapy for head and neck cancer
par: Matthew O. Old, et autres
Publié: (2016) -
Circulating tumor cells in head and neck cancer: A review
par: Kyle P. McMullen, et autres
Publié: (2016) -
The effect of treatment package time in head and neck cancer patients treated with adjuvant radiotherapy and concurrent systemic therapy
par: Ahmed I. Ghanem, et autres
Publié: (2019) -
Intra-tumor heterogeneity in head and neck cancer and its clinical implications
par: Edmund A. Mroz, et autres
Publié: (2016)